GSK744

From Wikipedia, the free encyclopedia
Jump to: navigation, search
GSK744
GSK744.svg
Identifiers
CAS number 1051375-10-0 N
Jmol-3D images Image 1
Properties
Molecular formula C19H17F2N3O5
Molar mass 405.35 g mol−1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 N
Infobox references

GSK744 (also known as S/GSK1265744 or with proposed unconfirmed name cabotegravir) is an investigational new drug under development for the treatment of HIV infection. It is an integrase inhibitor, with a carbamoyl pyridone structure similar to dolutegravir. In investigational studies, the agent has been packaged into nanoparticles (GSK744LAP) conferring an exceptionally long half-life of 21–50 days following a single dose. In theory, this would make possible suppression of HIV with dosing as infrequently as once every three months.[1]

References[edit]

  1. ^ PrEP GSK744 Integrase Administered Monthly Perhaps Quarterly Prevents HIV-Infection in Monkeys. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA March 3–6, 2013.